Advances in the understanding of Acute Myeloid Leukemia (AML) cell biology in recent years have unleashed a wave of new product development and treatment options available to patients.
This market evolution will continue to accelerate, with dozens of Phase 3 trials in progress addressing both adult and childhood AML treatment needs.
Capitalizing on our unique expertise in the AML market and in patient chart-based research, AMLsyndiTrackTM, our AML syndicated study uses real-world data to monitor the evolution of AML management.
Example of recent releases:- Data collected in October 21 in FR, DE, AT, CA
- other available data from 2021 in the UK, IT, ES, BE, the NL, CH, SW...
- over 750 interviews of Onco-Hematologists
- over 5,600 real-world patient charts analyzed